A chimeric antigen receptor-based cellular safeguard mechanism for selective in vivo depletion of engineered T cells.

ABSTRACT: Adoptive immunotherapy based on chimeric antigen receptor (CAR)-engineered T cells has exhibited impressive clinical efficacy in treating B-cell malignancies. However, the potency of CAR-T cells carriethe potential for significant on-target/off-tumor toxicities when target antigens are shared with healthy cells, necessitating the development of complementary safety measures. In this context, there is a need to selectively eliminate therapeutically administered CAR-T cells, especially to revert long-term CAR-T cell-related side effects. To address this, we have developed an effective cellular-based safety mechanism to specifically target and eliminate the transferred CAR-T cells. As proof-of-principle, we have designed a secondary CAR (anti-CAR CAR) capable of recognizing a short pep

SUBMITTER: Svec M 

PROVIDER: S-EPMC10808742 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature